---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038800"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T04:58:54.682239+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Indaptus reports Phase 1 interim data for Decoy20: biomarker activation & transient AEs in first cohort

## Summary
- Interim data from first cohort (n=4) of Phase 1 INDP-D101 trial for Decoy20, dosed at 7x10^7 killed bacteria via 1-hour IV infusion.
- Treatment-related AEs included changes in hemodynamic parameters, transaminase elevations, lymphopenia; all resolved within 30 min to 3 days.
- Transient activation of innate and/or adaptive immune biomarkers observed in all patients as of Aug 31, 2023.
- Company to present full interim data at SITC 38th Annual Meeting on November 4, 2023.

## SEC filing metadata
- accession: 0001493152-23-038800
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223038800/0001493152-23-038800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223038800/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038800
- JSON: https://secwatch.observer/filing/0001493152-23-038800.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.